跳至主要内容
临床试验/NCT03340480
NCT03340480已完成1 期

The Food Effect on the Pharmacokinetics of NVP-1402

NVP Healthcare1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2017年12月12日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
32
试验地点
1
主要终点
Pharmacokinetics of plasma: Cmax

研究概览

简要总结

The purpose of this study is to evaluate the food effect on the pharmacokinetics of NVP-1402 in healthy male volunteers.

详细描述

This study is designed as randomized, open-label, single oral dose, two-treatment, two sequence crossover active-controlled and crossover assignment for evaluate the food effect on the pharmacokinetics of NVP-1402 in healthy male subjects.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Screening
盲法
None

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Healthy males
  • No history of clinically significant medical disorder
  • Capable of consent to participate in the study

排除标准

  • History of hypersensitive reactions to study drug or other related drugs
  • Any significant abnormality found during screening
  • Any significant medical history
  • History of alcohol abuse, smoking continuously
  • History of drug abuse
  • Clinically significant surgery within 4 weeks prior to administration of the study drug
  • Participation in another clinical trial within 3 months prior to administration of the study drug

研究组 & 干预措施

NVP-1402-1

Experimental

NVP-1402 was administered once a day for 24 hours

干预措施: NVP-1402 (Drug)

NVP-1402-2

Experimental

NVP-1402 was administered once a day for 24 hours

干预措施: NVP-1402 (Drug)

结局指标

主要结局

Pharmacokinetics of plasma: Cmax

时间窗: up to 24 hours after administration

Maximum measured concentration of the analyte in plasma

Pharmacokinetics of plasma: AUClast

时间窗: up to 24 hours after administration

Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point

次要结局

  • Pharmacokinetics of plasma: AUCinf(up to 24 hours after administration)
  • Pharmacokinetics of plasma: Tmax(up to 24 hours after administration)
  • Pharmacokinetics of plasma: t1/2(up to 24 hours after administration)

研究者

发起方
NVP Healthcare
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验